Takeda hops onto $61M round for CRISPR player synthesizing Cas9 alternatives
Takeda Ventures and OrbiMed have helped pump $61 million into a New York biotech joining the rush to dramatically expand the CRISPR tool kit.
One crucial component in the CRISPR gene editing process is a nuclease that cuts the target DNA once it’s led there by a guide RNA. Cas9 is the most well known and broadly used among them, although researchers have been coming up with a variety of alternatives. The one that Emendo Biotherapeutics will be advancing with its new funding is dubbed OMNI.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
